{"slideshow_credits": null, "snippet": "The study of Zytiga from Johnson & Johnson also showed that it could pose a competitive threat to a rival drug, Provenge from Dendreon.", "abstract": "Johnson & Johnson says its new prostate cancer drug Zytiga is effective when used earlier during treatment than it is now, potentially broadening its use and also posing a competitive threat to a rival drug, Dendreon's Provenge.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2012/03/09/business/trial-shows-benefit-in-earlier-use-of-zytiga-for-prostate-cancer.html", "lead_paragraph": "The study of Zytiga from Johnson & Johnson also showed that it could pose a competitive threat to a rival drug, Provenge from Dendreon.", "headline": {"seo": "Trial Shows Benefit in Earlier Use of Zytiga", "main": "Trial Shows Benefit in Using Prostate Cancer Drug Early", "print_headline": "Trial Shows Benefit in Using Prostate Cancer Drug Early"}, "_id": "53f46c8a38f0d857ea2d100f", "word_count": "546", "multimedia": [], "pub_date": "2012-03-09T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Prostate Cancer", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Johnson & Johnson", "name": "organizations", "is_major": "Y", "rank": "4"}, {"value": "Research", "name": "subject", "is_major": "N", "rank": "5"}], "blog": [], "subsection_name": null, "type_of_material": "News"}